Mabvax Therapeutics Holdings Inc (MBVX) 4.74 $MBVX
Post# of 273254
Posted On: 09/21/2016 5:19:13 PM
Mabvax Therapeutics Holdings Inc (MBVX) 4.74 $MBVX
MabVax Delivering 1-2 Punch with "Diagnose and Destroy" Cancer Pipeline
PR Newswire - Tue Sep 20, 7:30AM CDT
By Financial Press Staff
MBVX: 4.74 (-0.10)
MabVax Therapeutics Reports on Interim Progress on Its Programs Including the Phase I Clinical Trial for Therapeutic Antibody Treatment of Pancreatic Cancer
PR Newswire - Mon Sep 19, 8:05AM CDT
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company reported on the early progress of its lead therapeutic antibody program, MVT-5873, currently in a phase I clinical trial in patients with pancreatic cancer and other CA19.9 positive malignancies. This trial is designed to establish safety, a recommended phase II dose (RP2D), and evaluate pharmacokinetics of MVT-5873, both as a monotherapy and in combination with the current standard of care chemotherapy. The site investigators for the phase I trial are monitoring patient blood chemistry and hematology for safety as well as disease status using the standard RECIST 1.1 criteria to evaluate tumor response rate and duration of response. The trial was initiated in February of this year. Three clinical investigation sites are currently enrolling patients: Memorial Sloan Kettering Cancer Center and two research sites in the Sara Cannon Research Institute network.
MBVX: 4.74 (-0.10)
Oncology Biotech Standout MabVax Therapeutics Interviewed on Small Cap Nation
PR Newswire - Fri Sep 16, 8:05AM CDT
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that Company CEO, David Hansen, was interviewed by Small Cap Nation's Jane King from the NASDAQ Marketsite in Times Square. Mr. Hansen provided an insightful update on the Company's recent positive events and upcoming near-term significant milestones. The interview in its entirety is available here.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Provides Webcast Presentation at Rodman & Renshaw Conference
PR Newswire - Thu Sep 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company, today announced that the Company's management has presented at the Rodman & Renshaw 18th Annual Global Investment Conference and is providing investors with a recorded webcast of its presentation available here: http://www.wsw.com/webcast/rrshq26/register.a...index.aspx
MBVX: 4.74 (-0.10)
MabVax Therapeutics Issues Letter to Shareholders Post Uplisting onto the Nasdaq Capital Market
PR Newswire - Thu Sep 08, 9:00AM CDT
MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, today announced the Company has issued a letter to shareholders discussing recent positive events and upcoming near-term significant milestones.
MBVX: 4.74 (-0.10)
StockNewsNow.com Publishes New Video Interview with MabVax Therapeutics Holdings, Inc. Discussing Clinical Developments, Goals and Milestones for 2016
PR Newswire - Wed Sep 07, 8:30AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an In-Studio SNNLive Video Interview with David Hansen, President and CEO of MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, according to the Company's website www.MabVax.com. The video interview was recorded in our studio in Los Angeles, CA on August 22nd, 2016.
MBVX: 4.74 (-0.10)
MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Aug 31, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, announced today that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic Cancer
PR Newswire - Mon Jun 13, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of a second investigational Phase I site for MVT-5873 (HuMab-5B1) with Sarah Cannon Research Institute through its network of research sites. The product is for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. In addition to the Sarah Cannon Research Institute at Tennessee Oncology site in Nashville, Tenn., patient enrollment in the Phase I trial is underway within Sarah Cannon Research Institute at Florida Cancer Specialists in Sarasota, Fla.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center
PR Newswire - Tue Jun 07, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of patient enrollment at Memorial Sloan Kettering Cancer Center (MSK) in the Phase I clinical trial evaluating its leading clinical development product MVT-5873 (HuMab-5B1) as a therapeutic treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. This is the second investigational site in the Phase I trial with patient recruitment currently underway at the Sarah Cannon Research Institute in Nashville, TN. MabVax previously announced receipt of authorization to proceed on the Investigational New Drug (IND) application filed from U.S. Food and Drug Administration (FDA).
MBVX: 4.74 (-0.10)
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress
PR Newswire - Thu May 19, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that Paul Maffuid, PhD, Executive Vice President of Research and Development, will discuss MabVax's unique approach to the discovery of fully human antibodies to cancer antigens and the resulting lead HuMab-5B1 clinical projects in a presentation at America's Antibody Congress in San Diego on May 19-20, 2016.
MBVX: 4.74 (-0.10)
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
PR Newswire - Mon May 16, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its lead cancer therapeutic HuMab-5B1 (MVT-5873) was featured in a poster presentation on May 13th at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, held in Orlando, Florida. MVT-5873 is currently being evaluated in an open-label, multicenter, dose-escalation Phase I clinical trial as a single agent and in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
MBVX: 4.74 (-0.10)
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans
PR Newswire - Mon Apr 18, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its fully human antibody approach to cancer therapeutics and imaging will be featured in three separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting currently underway in New Orleans.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer
PR Newswire - Fri Apr 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for our products under development.
MBVX: 4.74 (-0.10)
MabVax Therapeutics to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 03, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference is being held at The Waldorf Astoria New York hotel in New York City.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Feb 01, 9:37AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. The Company filed an Investigational New Drug (IND) application for this trial with the FDA on December 29, 2015. MabVax previously announced receipt of FDA authorization for a Phase I trial with HuMab-5B1 as a therapeutic treatment for patients with pancreatic cancer, and patient enrollment in both Phase I trials is expected to commence in the first quarter of 2016.
MBVX: 4.74 (-0.10)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.22 (unch), MBVX: 4.74 (-0.10), PFE: 34.28 (+0.47), AMGN: 173.85 (+0.47), SPPI: 4.47 (-0.15), BIND: 0.78 (-0.09), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), GSK: 43.21 (+0.15), MEIP: 1.75 (-0.01), MRK: 62.70 (+0.76), ABBV: 64.10 (+0.82), NVS: 81.52 (+0.46), KPTI: 9.57 (+0.37), ARRY: 3.59 (-0.05), EXEL: 14.74 (+0.58)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 4.74 (-0.10), PCYC: 261.25 (+1.70), AMPE: 0.89 (+0.01), GSK: 43.21 (+0.15), MEIP: 1.75 (-0.01), AAAP: 38.42 (-0.11), MACK: 5.08 (+0.42), PGNX: 6.24 (+0.06), BLCM: 19.65 (-0.06), CYCC: 5.88 (-0.10), RXDX: 6.17 (-0.29), MRK: 62.70 (+0.76), AZN: 33.75 (+0.10), JUNO: 31.32 (+1.57), CBLI: 1.67 (-0.03), NVS: 81.52 (+0.46), CELGZ: 1.25 (+0.05)
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
PR Newswire - Tue Jan 19, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today that it has closed on the first part of a financing agreement with a leading life sciences and healthcare lender. The financing agreement will provide the Company with up to $10 million in senior secured debt financing. The Company received an initial loan of $5 million, before approximately $381,000 in issuances costs, with an additional $5 million to be released contingent upon achieving certain milestones. The net proceeds of the initial tranche of debt financing will supplement the Company's cash position, following a $2.75 million public offering which the Company previously announced was completed in October 2015. The proceeds of the debt financing transaction, together with the public offering, will help advance the Company's lead antibody-based product HuMab-5B1, recently authorized by the U.S. Food and Drug Administration (FDA) to proceed with the first of two Phase 1 clinical trials, in 2016. The funds will also be used to advance other anti-body and diagnostic products in the pipeline in 2016.
MBVX: 4.74 (-0.10)
MabVax Delivering 1-2 Punch with "Diagnose and Destroy" Cancer Pipeline
PR Newswire - Tue Sep 20, 7:30AM CDT
By Financial Press Staff
MBVX: 4.74 (-0.10)
MabVax Therapeutics Reports on Interim Progress on Its Programs Including the Phase I Clinical Trial for Therapeutic Antibody Treatment of Pancreatic Cancer
PR Newswire - Mon Sep 19, 8:05AM CDT
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical stage immuno-oncology drug development company reported on the early progress of its lead therapeutic antibody program, MVT-5873, currently in a phase I clinical trial in patients with pancreatic cancer and other CA19.9 positive malignancies. This trial is designed to establish safety, a recommended phase II dose (RP2D), and evaluate pharmacokinetics of MVT-5873, both as a monotherapy and in combination with the current standard of care chemotherapy. The site investigators for the phase I trial are monitoring patient blood chemistry and hematology for safety as well as disease status using the standard RECIST 1.1 criteria to evaluate tumor response rate and duration of response. The trial was initiated in February of this year. Three clinical investigation sites are currently enrolling patients: Memorial Sloan Kettering Cancer Center and two research sites in the Sara Cannon Research Institute network.
MBVX: 4.74 (-0.10)
Oncology Biotech Standout MabVax Therapeutics Interviewed on Small Cap Nation
PR Newswire - Fri Sep 16, 8:05AM CDT
MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, today announced that Company CEO, David Hansen, was interviewed by Small Cap Nation's Jane King from the NASDAQ Marketsite in Times Square. Mr. Hansen provided an insightful update on the Company's recent positive events and upcoming near-term significant milestones. The interview in its entirety is available here.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Provides Webcast Presentation at Rodman & Renshaw Conference
PR Newswire - Thu Sep 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage oncology drug development company, today announced that the Company's management has presented at the Rodman & Renshaw 18th Annual Global Investment Conference and is providing investors with a recorded webcast of its presentation available here: http://www.wsw.com/webcast/rrshq26/register.a...index.aspx
MBVX: 4.74 (-0.10)
MabVax Therapeutics Issues Letter to Shareholders Post Uplisting onto the Nasdaq Capital Market
PR Newswire - Thu Sep 08, 9:00AM CDT
MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, today announced the Company has issued a letter to shareholders discussing recent positive events and upcoming near-term significant milestones.
MBVX: 4.74 (-0.10)
StockNewsNow.com Publishes New Video Interview with MabVax Therapeutics Holdings, Inc. Discussing Clinical Developments, Goals and Milestones for 2016
PR Newswire - Wed Sep 07, 8:30AM CDT
StockNewsNow.com, The Official MicroCap News Source(TM), today published an In-Studio SNNLive Video Interview with David Hansen, President and CEO of MabVax Therapeutics Holdings, Inc. (NASDAQ: MBVX), a clinical-stage oncology drug development company, according to the Company's website www.MabVax.com. The video interview was recorded in our studio in Los Angeles, CA on August 22nd, 2016.
MBVX: 4.74 (-0.10)
MabVax Therapeutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
PR Newswire - Wed Aug 31, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (NasdaqCM: MBVX), a clinical-stage oncology drug development company, announced today that it will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel, New York City.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Launches Second Investigational Site with Sarah Cannon Research Institute in Ongoing Phase I Clinical Trial to Evaluate New Treatment for Pancreatic Cancer
PR Newswire - Mon Jun 13, 8:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of a second investigational Phase I site for MVT-5873 (HuMab-5B1) with Sarah Cannon Research Institute through its network of research sites. The product is for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. In addition to the Sarah Cannon Research Institute at Tennessee Oncology site in Nashville, Tenn., patient enrollment in the Phase I trial is underway within Sarah Cannon Research Institute at Florida Cancer Specialists in Sarasota, Fla.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Expands Patient Enrollment in Phase I Trial for Treatment of Pancreatic Cancer to Memorial Sloan Kettering Cancer Center
PR Newswire - Tue Jun 07, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the initiation of patient enrollment at Memorial Sloan Kettering Cancer Center (MSK) in the Phase I clinical trial evaluating its leading clinical development product MVT-5873 (HuMab-5B1) as a therapeutic treatment for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies. This is the second investigational site in the Phase I trial with patient recruitment currently underway at the Sarah Cannon Research Institute in Nashville, TN. MabVax previously announced receipt of authorization to proceed on the Investigational New Drug (IND) application filed from U.S. Food and Drug Administration (FDA).
MBVX: 4.74 (-0.10)
MabVax Therapeutics' Antibody Discovery Platform and HuMab-5B1 Cancer Therapeutic Featured in Presentation at America's Antibody Congress
PR Newswire - Thu May 19, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that Paul Maffuid, PhD, Executive Vice President of Research and Development, will discuss MabVax's unique approach to the discovery of fully human antibodies to cancer antigens and the resulting lead HuMab-5B1 clinical projects in a presentation at America's Antibody Congress in San Diego on May 19-20, 2016.
MBVX: 4.74 (-0.10)
MabVax Therapeutics' HuMab-5B1 Cancer Therapeutic Featured in Presentation at AACR Special Meeting on Pancreatic Cancer
PR Newswire - Mon May 16, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its lead cancer therapeutic HuMab-5B1 (MVT-5873) was featured in a poster presentation on May 13th at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, held in Orlando, Florida. MVT-5873 is currently being evaluated in an open-label, multicenter, dose-escalation Phase I clinical trial as a single agent and in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
MBVX: 4.74 (-0.10)
MabVax Therapeutics' Fully Human Antibody Approach to Cancer Therapeutics and Imaging Featured in Three Presentations at AACR Annual Meeting in New Orleans
PR Newswire - Mon Apr 18, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that its fully human antibody approach to cancer therapeutics and imaging will be featured in three separate poster presentations at the American Association for Cancer Research (AACR) Annual Meeting currently underway in New Orleans.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Holdings Hires Paul Resnick, M.D. as Chief Business Officer
PR Newswire - Fri Apr 15, 7:00AM CDT
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug development company, announces the hiring of Paul Resnick, M.D., M.B.A. to the newly created position of Vice President and Chief Business Officer, responsible for corporate development, including engaging with large pharmaceutical and biotechnology companies on potential licensing and collaboration arrangements for our products under development.
MBVX: 4.74 (-0.10)
MabVax Therapeutics to Present at BIO CEO & Investor Conference
PR Newswire - Wed Feb 03, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage immuno-oncology drug development company, announces that President and Chief Executive Officer David Hansen is scheduled to present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016, at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). The conference is being held at The Waldorf Astoria New York hotel in New York City.
MBVX: 4.74 (-0.10)
MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer
PR Newswire - Mon Feb 01, 9:37AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. The Company filed an Investigational New Drug (IND) application for this trial with the FDA on December 29, 2015. MabVax previously announced receipt of FDA authorization for a Phase I trial with HuMab-5B1 as a therapeutic treatment for patients with pancreatic cancer, and patient enrollment in both Phase I trials is expected to commence in the first quarter of 2016.
MBVX: 4.74 (-0.10)
World Small-Cell Lung Cancer Therapeutic Development Pipeline Review, H2 2015
M2 - Fri Jan 29, 5:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/3zbk4w/smallcell_lung) has announced the addition of the "Small-Cell Lung Cancer - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Small-Cell Lung Cancer Overview - Therapeutics Development - Pipeline Products for Small-Cell Lung Cancer - Overview - Pipeline Products for Small-Cell Lung Cancer - Comparative Analysis - Small-Cell Lung Cancer - Therapeutics under Development by Companies - Small-Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Small-Cell Lung Cancer - Products under Development by Companies - Small-Cell Lung Cancer - Products under Investigation by Universities/Institutes - Small-Cell Lung Cancer - Companies Involved in Therapeutics Development - 3B Pharmaceuticals GmbH - 4SC AG - A. Menarini Industrie Farmaceutiche Riunite Srl - AbbVie Inc. - Alchemia Limited - Amgen Inc. - Andarix Pharmaceuticals, Inc. - Aposense Ltd. - Array BioPharma Inc. - Astellas Pharma Inc. - BIND Therapeutics, Inc. - Blend Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Eli Lilly and Company - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - G1 Therapeutics, Inc. - Genzyme Corporation - GlaxoSmithKline Plc - Karyopharm Therapeutics, Inc. - Kolltan Pharmaceuticals, Inc. - Kyowa Hakko Kirin Co., Ltd. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MedImmune, LLC - MEI Pharma, Inc. - Merck & Co., Inc. - NanoSmart Pharmaceuticals, Inc. - Nippon Kayaku Co., Ltd. - Novartis AG - Pfizer Inc. - Polaris Pharmaceuticals, Inc. - Rexahn Pharmaceuticals, Inc. - Spectrum Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/3z...lcell_lung
RNN: 0.22 (unch), MBVX: 4.74 (-0.10), PFE: 34.28 (+0.47), AMGN: 173.85 (+0.47), SPPI: 4.47 (-0.15), BIND: 0.78 (-0.09), LLY: 80.87 (+0.99), BMY: 55.93 (+0.37), GSK: 43.21 (+0.15), MEIP: 1.75 (-0.01), MRK: 62.70 (+0.76), ABBV: 64.10 (+0.82), NVS: 81.52 (+0.46), KPTI: 9.57 (+0.37), ARRY: 3.59 (-0.05), EXEL: 14.74 (+0.58)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
MBVX: 4.74 (-0.10), PCYC: 261.25 (+1.70), AMPE: 0.89 (+0.01), GSK: 43.21 (+0.15), MEIP: 1.75 (-0.01), AAAP: 38.42 (-0.11), MACK: 5.08 (+0.42), PGNX: 6.24 (+0.06), BLCM: 19.65 (-0.06), CYCC: 5.88 (-0.10), RXDX: 6.17 (-0.29), MRK: 62.70 (+0.76), AZN: 33.75 (+0.10), JUNO: 31.32 (+1.57), CBLI: 1.67 (-0.03), NVS: 81.52 (+0.46), CELGZ: 1.25 (+0.05)
MabVax Therapeutics Holdings Executes a Debt Facility for up to $10 million
PR Newswire - Tue Jan 19, 7:00AM CST
MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company announced today that it has closed on the first part of a financing agreement with a leading life sciences and healthcare lender. The financing agreement will provide the Company with up to $10 million in senior secured debt financing. The Company received an initial loan of $5 million, before approximately $381,000 in issuances costs, with an additional $5 million to be released contingent upon achieving certain milestones. The net proceeds of the initial tranche of debt financing will supplement the Company's cash position, following a $2.75 million public offering which the Company previously announced was completed in October 2015. The proceeds of the debt financing transaction, together with the public offering, will help advance the Company's lead antibody-based product HuMab-5B1, recently authorized by the U.S. Food and Drug Administration (FDA) to proceed with the first of two Phase 1 clinical trials, in 2016. The funds will also be used to advance other anti-body and diagnostic products in the pipeline in 2016.
MBVX: 4.74 (-0.10)
(0)
(0)Scroll down for more posts ▼